Fig. 2: The therapeutic effect of SB743921 on CCA cell lines.
From: The therapeutic effect of KSP inhibitors in preclinical models of cholangiocarcinoma
A, B Cell sensitivity to drugs treatment. CCA cell line HCCC-9810, RBE, CC143476, TFK1, SK-CHA-1, and normal counterpart cell line HIBEpiC were treated with drugs at gradient concentrations (0.001, 0.01, 0.1, 1 μM) for 72 h. Values shown in the chart are the mean percent viability of control ± SD obtained from three independent experiments. C Cell sensitivity to gemcitabine treatment. D Colony formation assay of HCCC-9810, RBE, and TFK1 cells after drugs treatment (0.01 μM, 7 days). Drugs were paclitaxel (PTX), docetaxel (DXT), cabazitaxel (CAB), vincristine (VCR), and cephalomannine (CEP), homoharringtonine (HHT) or gemcitabine (GEM). Bar graphs show representative data from three independent experiments. E Cell viability assessment of HCCC-9810, CCLP1, TFK1, and RBE cells treated with drugs (0.25 μM, 24 h) by PI staining. Bar graphs show the mean percentage of PI-positive cells from three independent experiments. F, G Immunoblot analyses of the expression of PARP, p-CHK1, p-P53, p-H2A.x, and c-Caspase3 in CCLP1 and TFK1 cells after drugs treatment (0.25 μM, 24 h).
